{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T04:02:08Z","timestamp":1775275328671,"version":"3.50.1"},"reference-count":17,"publisher":"Japan Endocrine Society","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Endocr J"],"published-print":{"date-parts":[[2026]]},"DOI":"10.1507\/endocrj.ej25-0204","type":"journal-article","created":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T22:08:15Z","timestamp":1766441295000},"page":"539-544","source":"Crossref","is-referenced-by-count":0,"title":["How to discontinue potassium iodide in combined therapy with methimazole for initial treatment of Graves\u2019 disease"],"prefix":"10.1507","volume":"73","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6433-9869","authenticated-orcid":false,"given":"Tsukasa","family":"Murakami","sequence":"first","affiliation":[{"name":"Department of Endocrinology, Noguchi Thyroid Clinic and Hospital Foundation, Beppu 874-0902, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoyuki","family":"Higaki","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Noguchi Thyroid Clinic and Hospital Foundation, Beppu 874-0902, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yui","family":"Nishijima","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Noguchi Thyroid Clinic and Hospital Foundation, Beppu 874-0902, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junichi","family":"Tani","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Noguchi Thyroid Clinic and Hospital Foundation, Beppu 874-0902, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hitoshi","family":"Noguchi","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Noguchi Thyroid Clinic and Hospital Foundation, Beppu 874-0902, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"386","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1 Watanabe N (2025) A narrative review of long-term inorganic iodine monotherapy for Graves\u2019 disease with a historical relationship between iodine and thyroid. Endocr J 72: 23\u201336.","DOI":"10.1507\/endocrj.EJ24-0186"},{"key":"2","doi-asserted-by":"publisher","unstructured":"2 Uchida T, Goto H, Kasai T, Komiya K, Takeno K, et al. (2014) Therapeutic effectiveness of potassium iodine in drug-na\u00efve patients with Graves\u2019 disease: a single-center experience. Endocrine 47: 506\u2013511.","DOI":"10.1007\/s12020-014-0171-8"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 Suzuki N, Yoshimura Noh J, Sugisawa C, Hoshiyama A, Hiruma M, et al. (2020) Therapeutic efficacy and limitations of potassium iodide for patients newly diagnosed with Graves\u2019 disease. Endocr J 67: 631\u2013638.","DOI":"10.1507\/endocrj.EJ19-0379"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 Okamura K, Sato K, Fujikawa M, Bandai S, Ikenoue H, et al. (2014) Remission after potassium iodide therapy in patients with Graves\u2019 hyperthyroidism exhibiting thionamide-associated side effects. J Clin Endocrinol Metab 99: 3995\u20134002.","DOI":"10.1210\/jc.2013-4466"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Okamura K, Sato K, Fujikawa M, Bandai S, Ikenoue H, et al. (2022) Iodide-sensitive Graves\u2019 hyperthyroidism and the strategy for resistant or escaped patients during potassium iodide treatment. Endocr J 69: 983\u2013997.","DOI":"10.1507\/endocrj.EJ21-0436"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Fujikawa M, Okamura K (2024) Graves\u2019 hyperthyroidism treated with potassium iodide: early response and after 2 years of follow-up. Eur Thyroid J 13: e240085.","DOI":"10.1530\/ETJ-24-0085"},{"key":"7","unstructured":"7 Japan Thyroid Association (ed) (2019) Guideline for the treatment of Graves\u2019 disease in Japan. Nankodo, Tokyo, Japan: 56\u201357 (In Japanese)."},{"key":"8","unstructured":"8 Japan Thyroid Association Guidelines for the Diagnosis of Graves\u2019 Disease. https:\/\/www.japanthyroid.jp\/doctor\/guideline\/japanese.html accessed on April 15, 2025 (In Japanese)."},{"key":"9","doi-asserted-by":"crossref","unstructured":"9 Wolff J, Chaikoff IL (1948) Plasma inorganic iodide as a homeostatic regulator of thyroid function. J Biol Chem 174: 555\u2013564.","DOI":"10.1016\/S0021-9258(18)57335-X"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10 Goldsmith RE, Eisele ML (1956) The effect of iodide on the release of thyroid hormone in hyperthyroidism. J Clin Endocrinol Metab 16: 130\u2013137.","DOI":"10.1210\/jcem-16-1-130"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11 Kasai K, Suzuki H, Shimoda SI (1980) Effects of propylthiouracil and relatively small doses of iodide on early phase treatment of hyperthyroidism. Acta Endocrinol (Copenh) 93: 315\u2013321.","DOI":"10.1530\/acta.0.0930315"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 Roti E, Robuschi G, Gardini E, Montermini M, Salvi M, et al. (1988) Comparison of methimazole, methimazole and sodium ipodate, and methimazole and saturated solution of potassium iodide in the early treatment of hyperthyroid Graves\u2019 disease. Clin Endocrinol (Oxf) 28: 305\u2013314.","DOI":"10.1111\/j.1365-2265.1988.tb01217.x"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13 Takata K, Amino N, Kubota S, Sasaki I, Nishihara E, et al. (2010) Benefit of short-term iodide supplementation to antithyroid drug treatment of thyrotoxicosis due to Graves\u2019 disease. Clin Endocrinol (Oxf) 72: 845\u2013850.","DOI":"10.1111\/j.1365-2265.2009.03745.x"},{"key":"14","doi-asserted-by":"publisher","unstructured":"14 Sato S, Noh JY, Sato S, Suzuki M, Yasuda S, et al. (2015) Comparison of efficacy and adverse effects between methimazole 15 mg + inorganic iodine 38 mg\/day and methimazole 30 mg\/day as initial therapy for Graves\u2019 disease patients with moderate to severe hyperthyroidism. Thyroid 25: 43\u201350.","DOI":"10.1089\/thy.2014.0084"},{"key":"15","doi-asserted-by":"publisher","unstructured":"15 Takata K, Kubota S, Fukata S, Kudo T, Nishihara E, et al. (2009) Methimazole-induced agranulocytosis in patients with Graves\u2019 disease is more frequent with an initial dose of 30 mg daily than with 15 mg daily. Thyroid 19: 559\u2013563.","DOI":"10.1089\/thy.2008.0364"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16 Takizawa H, Uchida T, Suzuki N, Onose H, Yamada E, et al. (2025) Influence of therapeutic inorganic iodine on long-term prognosis of Graves\u2019 disease: a multicenter prospective observational study. Endocr J 72: 663\u2013670.","DOI":"10.1507\/endocrj.EJ24-0575"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17 Yabuta T, Ito Y, Hirokawa M, Fukushima M, Inoue H, et al. (2009) Preoperative administration of excess iodide increases thyroid volume of patients with Graves\u2019 disease. Endocr J 56: 371\u2013375.","DOI":"10.1507\/endocrj.K08E-240"}],"container-title":["Endocrine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/73\/4\/73_EJ25-0204\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T03:25:59Z","timestamp":1775273159000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/73\/4\/73_EJ25-0204\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":17,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1507\/endocrj.ej25-0204","relation":{},"ISSN":["0918-8959","1348-4540"],"issn-type":[{"value":"0918-8959","type":"print"},{"value":"1348-4540","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"article-number":"EJ25-0204"}}